Medical Devices Split at the Margin
Key points
- Butterfly Network beat revenue expectations with $32.6 million in second-quarter sales and raised its 2026 outlook.
- Butterfly's software and licensing mix lifted gross margin, but its net loss and cash use remain material.
- Haemonetics' August 6 report must pair its existing profitability with renewed revenue and earnings growth.
- Establishment Labs needs U.S. Motiva demand to support guidance and reduce the path to net profitability.
Butterfly Network, Inc. (
That company-level divide matters more than a broad healthcare label. The medical-device industry gained 8.4% in one month and 24.1% in three months, with 90.9% of names positive across the three-month period. The advance signals wide participation, but not a common earnings outcome. With prices already elevated, revenue quality, margin direction and guidance now provide the more useful read.
Butterfly's report offers evidence
On July 30, Butterfly Network provided the strongest fresh evidence in this small group. Second-quarter revenue reached $32.6 million, up 39% from the prior year and 11.8% above the $29.2 million consensus estimate. The company also reported a 71.4% gross margin, up from 63.7%, and raised its 2026 revenue outlook to $119 million to $123 million.
The mechanics matter. Butterfly sells portable ultrasound hardware, but its fast-growing software and other-services revenue reached $16.9 million in the quarter, slightly above product revenue. Management attributed the gross-margin gain partly to higher-margin Embedded licensing revenue and lower software amortization. It also said it signed six enterprise software agreements. If recurring software and licensing revenue continues to gain share, each additional dollar of sales has a better chance of carrying more gross profit than a hardware-heavy mix would.
That is a meaningful shift, not a finished turnaround. Butterfly still posted a $12.9 million net loss and used $30.2 million in operating cash during the first half. Its adjusted earnings before interest, taxes, depreciation, and amortization loss improved to $1.4 million, but adjusted measures do not replace the cash-flow test. The company guided to an adjusted EBITDA loss of $19 million to $23 million for the full year. The revenue beat therefore earns attention because the business mix improved, while the losses keep the proof standard high.
August 6 separates maturity from acceleration
Haemonetics reports fiscal first-quarter 2027 results before the market opens on August 6, followed by an 8 a.m. Eastern conference call. The company supplies blood and plasma collection technologies and hospital products, making it the established, profitable counterweight in this comparison. Consensus calls for $1.08 in earnings per share on $327.9 million in revenue.
Its recent market action leaves little room for a vague update. Haemonetics shares closed at $85.38 on August 4, only 2.2% below their 52-week high, after gaining 54.3% over three months. The company carries a 26.2 price-to-earnings ratio and reported an 18.1% operating margin. Yet its year-over-year revenue was down 2% and earnings per share fell 38.1% in the available data. For this report, investors need to see whether the mature operating base can restore growth without weakening profitability. A revenue shortfall or guarded outlook would carry more weight than a narrow earnings-per-share beat.
Establishment Labs also reports before the August 6 market open. It is a breast-aesthetics and reconstruction company whose Motiva product commercialization in the United States is central to the growth case. Consensus expects a $0.34 loss per share on $65.8 million in revenue.
The prior quarter shows why this name belongs on the growth-and-loss side of the comparison. First-quarter revenue rose 44.7% to $59.9 million, U.S. Motiva sales reached $19.6 million, and gross margin was 70.7%. Management raised full-year revenue guidance to $266.5 million to $268.5 million and forecast positive adjusted EBITDA in every quarter. Still, it reported a $13.4 million net loss and $7.1 million of interest expense. The August report needs to show that U.S. adoption is converting into revenue at a rate that supports the raised outlook and is narrowing the remaining gap to net profitability.
One tape, three different grades
The useful comparison is not only revenue growth. It is the route each company must take from demand to earnings. Butterfly has shown a mix-driven gross-margin improvement but remains loss-making and cash-consuming. Haemonetics already has positive operating profitability, so renewed top-line and earnings growth are the missing links. Establishment Labs has the fastest recent reported sales growth of the three, plus improving cost efficiency as it scales, but its net loss and interest costs leave execution less forgiving.
The price action reflects that different starting point. Butterfly closed at $8.81, up 81.6% over three months and 9.1% below its 52-week high. Establishment Labs closed at $94.61, up 34.7% over three months and 2.5% below its high. Both remain unprofitable on a trailing basis, so updated guidance and margin progression carry unusual importance. Haemonetics has moved closer to its high with a positive operating margin, but it must show that the recovery in its shares is connected to revenue and earnings progress.
The clinical model still sets the risk
A strong industry screen should not blur the risks. These are not interchangeable businesses. Butterfly's outlook depends on licensing, software adoption, probe sales, and commercialization milestones. Establishment Labs faces product adoption, regulatory clearance, commercialization, and financing risks that its own disclosures identify. Haemonetics remains exposed to customer demand across plasma, blood collection, and hospital markets. Reimbursement, procedure volumes, product safety, or a guidance reset can overwhelm a favorable sector tape.
There is a valuation risk as well. Butterfly and Establishment Labs trade at roughly 9.6 and 10.2 times sales, respectively, despite negative trailing earnings. Those multiples are not a verdict, but they make the market more sensitive to evidence that sales growth is translating into margin or cash progress. Haemonetics is profitable, though its recent growth data are softer. A broad advance cannot neutralize a company-specific miss.
The reports need to earn the rally
The most constructive reading is conditional. Butterfly's report established that a software and licensing mix can improve its economics. If Haemonetics pairs the August 6 release with renewed revenue growth and if Establishment Labs confirms U.S. Motiva demand while protecting its margin and outlook, the group's strength will have stronger fundamental footing.
The industry rally has set the pace, but the companies must now supply the evidence. A mature operator needs growth, and innovators need a credible route from revenue to durable profitability. The August 6 prints will show whether the rally is carrying receipts or merely carrying expectations.